Pharmaceuticals

Revenue of the Anti-CD20 Monoclonal Antibodies Market Predicted to Achieve $12.94 Billion by 2030, Driven by 7.5% CAGR

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the anti-cd20 monoclonal antibodies market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Anti-CD20 Monoclonal Antibodies Market expected to grow between 2026 and 2030?

The anti-cd20 monoclonal antibodies market size has shown significant growth in recent years. It is anticipated to increase from $9 billion in 2025 to $9.7 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. This historical expansion can be attributed to the approval and widespread utilization of rituximab, a rising prevalence of non-hodgkin’s lymphoma and chronic lymphocytic leukemia, increasing recognition of targeted therapies, the presence of hospital pharmacy distribution channels, and the broadening of intravenous administration routes.

The anti-cd20 monoclonal antibodies market is anticipated to show robust growth in the coming years. This market is set to reach $12.94 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.5%. Factors contributing to this growth during the forecast period include the introduction of obinutuzumab and ofatumumab biosimilars, wider uptake of subcutaneous formulations, rising investment in research and academic fields, the proliferation of ambulatory care centers, and a surging demand for anti-cd20 treatments across various autoimmune conditions. Key trends anticipated for the forecast period encompass an escalating use of monoclonal antibody therapies for B-cell malignancies, the creation of biosimilars and advanced anti-cd20 antibodies, the proliferation of subcutaneous and more patient-convenient administration methods, a heightened emphasis on individualized and targeted immunotherapy, and an increase in clinical trials and research within autoimmune and oncology areas.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp

Which Drivers Are Influencing Market Acceleration In The Anti-CD20 Monoclonal Antibodies Market?

An anticipated increase in autoimmune diseases is projected to drive the expansion of the anti-CD20 monoclonal antibodies market in the future. These conditions arise when the body’s immune system mistakenly perceives its own cells as harmful and initiates an assault. The rise in autoimmune disorders is attributed to increased exposure to environmental pollutants, which can compromise immune system control and provoke attacks on bodily tissues. Anti-CD20 monoclonal antibodies address autoimmune diseases by eradicating B cells, which are responsible for generating autoantibodies and inflammation. These antibodies assist in regulating the immune response and alleviating disease manifestations. As an illustration, data from February 2024, provided by Arthritis Australia, an Australia-based non-profit entity, indicates that approximately 562,378 Australians are expected to have RA by 2025, constituting 14% of all arthritis cases for that year. This figure is projected to climb by 33% to 748,721 individuals by 2040. This signifies an additional 186,343 Australians living with RA in 2040 relative to 2025. Consequently, the increasing prevalence of autoimmune diseases is fueling the expansion of the anti-CD20 monoclonal antibodies market.

What Leading Segments Are Studied In The Anti-CD20 Monoclonal Antibodies Market?

The anti-cd20 monoclonal antibodies market covered in this report is segmented –

1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications

5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users

Subsegments:

1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux

2) By Obinutuzumab: Gazyva, Biosimilar Candidates

3) By Ofatumumab: Arzerra, Kesimpta

4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab

What Upcoming Trends Are Likely To Define The Future Path Of The Anti-CD20 Monoclonal Antibodies Market?

Companies within the anti-CD20 monoclonal antibody market are prioritizing the creation of advanced products like obinutuzumab to address resistant or relapsed B-cell malignancies with greater efficacy. Obinutuzumab functions as a humanized type II anti-CD20 monoclonal antibody, engineered to specifically identify and eliminate CD20-positive B cells implicated in particular blood cancers and autoimmune conditions. For example, in March 2025, Roche, a Switzerland-based biopharmaceutical company, announced the US Food and Drug Administration (FDA)’s acceptance of a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) for its use in treating lupus nephritis. This acceptance is founded on favorable outcomes from the Phase III REGENCY study, which indicated an enhanced complete renal response (CRR) when administered alongside standard therapy compared to standard therapy alone. Consequently, Gazyva/Gazyvaro stands as the sole anti-CD20 monoclonal antibody to have demonstrated such a benefit in lupus nephritis, a severe inflammatory condition associated with lupus that can result in kidney failure.

Which Leading Companies Dominate The Anti-CD20 Monoclonal Antibodies Market Share?

Major companies operating in the anti-cd20 monoclonal antibodies market are F. Hoffmann-La Roche Ltd., Novartis AG, Biogen Idec, TG Therapeutics, Celltrion Inc., Shanghai Henlius Biotech Inc., Innovent Biologics, Dr. Reddy’s Laboratories Ltd., Genmab A/S, AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Sanofi SA, Bristol-Myers Squibb Company, Samsung Bioepis, Sandoz International GmbH, Amneal Pharmaceuticals LLC, Viatris Inc., Intas Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Ltd., Aurobindo Pharma Ltd., Biocon Biologics Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hetero Biopharma Ltd., Reliance Life Sciences Pvt. Ltd., Adello Biologics, Mabion SA, mAbxience, Probiomed S.A. de C.V., Prestige Biopharma Ltd., CinnaGen Co., JHL Biotech Inc., Amgen Biologics Pvt. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/anti-cd20-monoclonal-antibodies-global-market-report

How Does The Anti-CD20 Monoclonal Antibodies Market Perform Across Major Global Regions?

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Anti-CD20 Monoclonal Antibodies Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25693&type=smp

Browse Through More Reports Similar to the Global Anti-CD20 Monoclonal Antibodies Market 2026, By The Business Research Company

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Polyclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795